Jeena Sikho Lifecare Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Jeena Sikho Lifecare Ltd filed with BSE on 14 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Jeena Sikho Lifecare reported Q1 FY27 revenue from operations of INR224 crores, EBITDA of INR92 crores and PAT of INR65 crores, with management citing a 41% EBITDA margin and 28% PAT margin. Management said revenue grew 29% year-on-year, supported by higher patient footfalls, service network expansion and continued growth in the products business, while Panchakarma revenue grew 13% on higher IPD and daycare volumes. Management also discussed a reduction in government hospital business, a new ultra-luxury wellness property in Manali, ongoing OTC distribution talks with Entero, and one-off expenses related to advertising and software this quarter.
Numbers mentioned
Revenue from operations: INR224 crores (Q1 FY27)
p. 4
“In this quarter, our revenue from operations stood at INR224 crores, while EBITDA was INR92 crores and PAT was INR65 crores.”
Manish Grover, page 4 of the filed PDF · View the filing
EBITDA: INR92 crores (Q1 FY27)
p. 4
“In this quarter, our revenue from operations stood at INR224 crores, while EBITDA was INR92 crores and PAT was INR65 crores.”
Manish Grover, page 4 of the filed PDF · View the filing
EBITDA margin: 41% (Q1 FY27)
p. 4
“We delivered a 41% EBITDA margin and a 28% PAT margin.”
Manish Grover, page 4 of the filed PDF · View the filing
PAT margin: 28% (Q1 FY27)
p. 4
“We delivered a 41% EBITDA margin and a 28% PAT margin.”
Manish Grover, page 4 of the filed PDF · View the filing
Revenue growth YoY: 29% (Q1 FY27)
p. 4
“Revenue from operations grew by 29% YoY in Q1 FY27, supported by higher patient footfalls, expansion of our service network, and continued momentum in our products business.”
Nanak Chand, page 4 of the filed PDF · View the filing
EBITDA growth YoY: 17% (Q1 FY27)
p. 4
“Profitability remained robust, with EBITDA growing 17% on a YoY basis and EBITDA margin sustaining at a healthy 41%.”
Nanak Chand, page 4 of the filed PDF · View the filing
Panchakarma revenue growth: 13% (Q1 FY27)
p. 4
“Within our Ayurveda healthcare service business, underlying demand remained strong, with Panchakarma revenue growing 13% in Q1 FY27, supported by a 33% YoY increase in IPD patients and a 31% increase in day care volume.”
Nanak Chand, page 4 of the filed PDF · View the filing
Ayurveda product business growth: 47% YoY (Q1 FY27)
p. 5
“Our Ayurveda healthcare product business continued to perform strongly, growing 47% YoY during the quarter.”
Nanak Chand, page 5 of the filed PDF · View the filing
Medicine sales: INR118 crores (Q1 FY27)
p. 6
“For instance, medicine sales were INR80 crores in Q1 and INR118 crores in Q4, and this quarter too it is INR118 crores.”
Manish Grover, page 6 of the filed PDF · View the filing
Total sales: INR224 crores (Q1 FY27)
p. 6
“If you look overall, total sales were INR174 crores in Q1 last year, and in this Q1 it is INR224 crores.”
Manish Grover, page 6 of the filed PDF · View the filing
Government hospital business revenue: INR5 crores (Q1 FY27)
p. 6
“Government business came down from INR15 crores to INR5 crores in this quarter.”
Manish Grover, page 6 of the filed PDF · View the filing
Total connected patients/customers: 5,34,000 (Q1 FY27)
p. 7
“If I look at quarter 4 to quarter 1, then 5,34,000 people are connected to us in this quarter.”
Manish Grover, page 7 of the filed PDF · View the filing
Daycare volume: 19,400 (Q1 FY27)
p. 7
“So that number of daycare has increased from 16,700 to 19,400.”
Manish Grover, page 7 of the filed PDF · View the filing
IPD patients: 11,500 (Q1 FY27)
p. 8
“That went from 8,600 to 11,500 quarter-on-quarter, you are saying.”
Manish Grover, page 8 of the filed PDF · View the filing
One-time other income: INR7 crores (Q1 FY27)
p. 9
“So, in this, the one-time other income we have booked is around INR7 crores, in which around INR5 crores is warrant valuation and INR2.5 crores is capital gain income.”
Nanak Chand, page 9 of the filed PDF · View the filing
Advertisement budget increase: 25% (Q1 FY27)
p. 11
“So, we have increased the advertisement budget by 25% in this quarter, in which we have launched some new products, six to seven, and their additional benefit we will get in the coming quarters.”
Nanak Chand, page 11 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Bed capacity — 7,000 to 10,000 beds · next 3 to 5 years
stated firmly by Manish Grover
p. 5
“Our first strategy is to 7000 to 10,000 bed in the next 3 to 5 years, which I said in the last con call.”
Manish Grover, page 5 of the filed PDF · View the filing
Turnover — INR3000 crores · 3 to 5 years
stated firmly by Manish Grover
p. 5
“My turnover of INR3000 crores in about 3 years and I will achieve it maximum before 5 years.”
Manish Grover, page 5 of the filed PDF · View the filing
Revenue growth — 30% year-on-year
stated firmly by Manish Grover
p. 5
“And I will maintain a growth of about 30% year-on-year.”
Manish Grover, page 5 of the filed PDF · View the filing
PAT — INR1,000 crores · next three years
stated as an aspiration by Manish Grover
p. 9
“And I am working on INR1,000 crores PAT.”
Manish Grover, page 9 of the filed PDF · View the filing
OTC product availability via Entero — products across all Entero distributors · within 15 days
stated firmly by Manish Grover
p. 7
“They have completed their testing, and within 15 days, our products will start appearing across all their distributors.”
Manish Grover, page 7 of the filed PDF · View the filing
Manali ultra-luxury wellness EBITDA — 35% to 40% plus for year one · FY27/first 12 months
stated conditionally by Ankush Kaushal
p. 10
“So, with an average occupancy expected for the first 12 business months would be 50%, with an ADR of 32,000 to 35,000, and with overall gross margins of around 50% to 55%, with an EBITDA coming to approximately 35 % to 40 % plus for year one.”
Ankush Kaushal, page 10 of the filed PDF · View the filing
Manali wellness occupancy year two — 60% occupancy · year two
stated conditionally by Ankush Kaushal
p. 10
“And year two, we are looking at 60% occupancy with near about 7,700 occupied room nights with an ADR of 35,000 to 37,000, with overall gross operating margin of near about 60%, 62%, and at a very bare minimum operating cost of 9% to 10% only.”
Ankush Kaushal, page 10 of the filed PDF · View the filing
Additional luxury wellness centers — three to four more centers, INR3 to 5 crores profit each
stated as an aspiration by Manish Grover
p. 10
“And we are looking for more such deals in India, so we are planning to launch three to four such luxury premium wellness in four different corners of all over India, which will give us at least around INR3 crores to INR5 crores profit from each center, as we have thought.”
Manish Grover, page 10 of the filed PDF · View the filing
New discounted-rate beds scheme — 500 beds · within 10 days
stated firmly by Nanak Chand
p. 18
“I will start 500 beds in 10 days, in which I will start taking poor patients in INR4,000, INR5,000, INR6.000.”
Nanak Chand, page 18 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said patient volume grew 10% quarter-on-quarter, that government business was deliberately scaled down, and that the company should be judged on annual rather than quarterly performance.
Answered by Manish Grover
Asked by Karanveer Singh: Why does quarter-on-quarter revenue look flat despite good year-on-year growth, and where is the growth focus, products or services?
p. 5
“If you look at our patient count and volume, overall quarter-on-quarter growth is 10%.”
Manish Grover, page 5 of the filed PDF · View the filing
Management said Entero testing is complete and products will appear across their distributors within two weeks, and that the Satkartar agreement remains active.
Answered by Manish Grover
Asked by Pal Balar: What is the status of the OTC product tie-up with Entero and the Satkartar arrangement?
p. 7
“I spoke with the Entero team just this morning, and our team had a one-on-one Zoom meeting with them last week.”
Manish Grover, page 7 of the filed PDF · View the filing
Management attributed the gap to growth being concentrated in lower-ticket segments such as OPD, COD and consultations, with conversion into higher-value Panchakarma treatment occurring with a lag.
Answered by Manish Grover
Asked by Aditya Chheda: Why did IPD volume grow 33% and OPD 21% but healthcare services revenue grow only 11%?
p. 8
“Sir, we first guide the patient on ways to get well at home. We win the patient's faith.”
Manish Grover, page 8 of the filed PDF · View the filing
The CFO said about INR7 crores was one-time (warrant valuation and capital gains) and that a recurring base of INR4-5 crores from mutual funds and fixed deposits should continue.
Answered by Nanak Chand
Asked by Rusmik: Is the jump in other income from INR4 crores to INR14 crores a one-off, and how should it be modeled going forward?
p. 9
“So, in this, the one-time other income we have booked is around INR7 crores, in which around INR5 crores is warrant valuation and INR2.5 crores is capital gain income.”
Nanak Chand, page 9 of the filed PDF · View the filing
Management detailed roughly INR4 crores extra advertising, INR2 crores software implementation, and INR50 lakh higher audit costs, and said such spending would continue as part of ongoing investment for operating leverage.
Answered by Nanak Chand
Asked by Deepak Poddar: What one-off expenses were incurred this quarter and will they recur?
p. 11
“So, we have increased the advertisement budget by 25% in this quarter, in which we have launched some new products, six to seven, and their additional benefit we will get in the coming quarters.”
Nanak Chand, page 11 of the filed PDF · View the filing
Management said ticket sizes were reduced deliberately to admit lower-income patients at a discount ahead of Ayushman Yojana coverage, which lowered realization per patient.
Answered by Nanak Chand
Asked by Sunil: Why did Panchakarma revenue grow only 13% despite IPD and OPD volume growth of 33% and 22%?
p. 18
“Sir, there is one factor that I would like to explain you. That our incremental ticket size, our per patient, we have reduced our ticket size a little.”
Nanak Chand, page 18 of the filed PDF · View the filing
Management said it would check whether such an update is permissible under corporate governance norms and would provide it if possible.
Answered by Manish Grover
Asked by Priyanshu Jain: Can the company provide a quarterly business update shortly after quarter-end, ahead of formal results?
p. 20
“We will check, sir. If they can give it, then we will definitely give it.”
Manish Grover, page 20 of the filed PDF · View the filing
Management said nine products were launched but focus has shifted to e-commerce over traditional OTC due to high medical-store margin demands.
Answered by Management
Asked by Naveen Baid: How many OTC products have been launched and what is the plan for new launches?
p. 14
“In OTC also, the expense is quite high, sir. The medical store guy is asking for a 50% margin.”
Management, page 14 of the filed PDF · View the filing
Management said the property is leased from an individual owner for an initial three-year term, renewable in further three-year blocks.
Answered by Ankush Kaushal
Asked by Aashish: Is the Manali luxury wellness property leased, and for how long?
p. 16
“Right now, we have signed for three years contract to be further renewable on three plus three plus three.”
Ankush Kaushal, page 16 of the filed PDF · View the filing
Risks flagged
Government hospital receivables risk led management to deliberately reduce government business
p. 5
“If I continue business where money gets stuck in receivables, that bad debt risk persists.”
Manish Grover, page 5 of the filed PDF · View the filing
Seasonality in Manali due to cold weather limiting near-term revenue contribution
p. 10
“Not much will come in 27 because it is starting in October, September-October. In November-December, there is terrible cold.”
Manish Grover, page 10 of the filed PDF · View the filing
Regulatory delays such as fire and pollution NOCs affecting bed capacity expansion
p. 16
“Right now, Panvel's OC, fire, this is going on, so right now it is of 49 beds.”
Manish Grover, page 16 of the filed PDF · View the filing
Reduced ticket size from discounting for lower-income patients affecting realization
p. 18
“So this could be the reason.”
Nanak Chand, page 18 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.